GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Shares of Wockhardt Ltd. are trading with gains of 10% on Monday, December 16, after the company announced the successful use ...

Within days of use of the novel drug, the patient was cured of the infection. Zaynich by Mumbai-based pharma company ...

It is administered via intravenous [IV] infusion in hospitals, specifically for critically ill patients, and is not available over the counter,” Dr Maneesh Paul, the lead co-inventor of the drug, told ...

India's medical fraternity drove creative and cost-effective innovations, making 2024 a landmark year for medical ...

Habil Khorakiwala, Chairman of Wockhardt had previously said that once the trials are complete, the company will seek ...

Wockhardt's Zaynich antibiotic enables successful liver transplant for US cancer patient, shares soar, Phase III study nears ...

There is a need to laud India’s legislative atmosphere that allows patenting of drugs & encourages innovation. But the same law can also make life-saving medication prohibitively expensive ...

View all information regarding the medicines that are manufactured by Wockhardt Ltd. (Biotech) including its generic drug name, trade name, how to use, the price, and its composition.

India has developed a new antibiotic, nafithromycin (Miqnaf), to combat drug-resistant pneumonia. Developed by Wockhardt with BIRAC support, this first-of-its-kind Indian antibiotic is more potent ...

Mumbai-based Wockhardt is testing a new antibiotic, called Zaynich, for severe drug-resistant infections. Developed over 25 years, the drug is currently in Phase-3 trials and expected to launch ...